Allogene Therapeutics Inc (ALLO): Eigentümerstruktur
Der letzte verfügbare Schlusskurs ist 03.09.2026. Die angezeigten Informationen beziehen sich auf den historischen Stand und sind nicht tagesaktuell.
| Analysten Konsens | Buy | Outperform | Hold | Underperform | Sell |
| 9 US Dollar | 8 | 4 | 2 | 0 | 0 |
| #Shares | Short [%] | Short Ratio |
| 345.490.881 | 18,88 | 10,07 |
Eigentümerstruktur
Analyse der Aktionärsstruktur und institutionellen Investoren
Unternehmensdaten
Grundlegende Informationen
Grunddaten
Name Allogene Therapeutics Inc
Mitarbeiter 150
Handelsplatz NASDAQ
Ticker Symbol ALLO
IPO Datum 2018-10-11
Adresse 210 East Grand Avenue, South San Francisco, CA, United States, 94080
Webseite https://allogene.com
Unternehmensführung
| Rang | Name | Position |
|---|---|---|
| 1 | Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder & Executive Chairman |
| 2 | Dr. Zachary J. Roberts M.D., Ph.D. | President, CEO & Director |
| 3 | Mr. Joshua A. Kazam | Co-Founder & Director |
| 4 | Dr. David D. Chang M.D., Ph.D. | Co-Founder & Director |
| 5 | Mr. Geoffrey M. Parker | Executive VP & CFO |
| 6 | Mr. Benjamin M. Beneski | Senior VP & Chief Technical Officer |
| 7 | Mr. Earl M. Douglas Esq. | Senior VP, General Counsel, Compliance Officer & Corporate Secretary |
| 8 | Ms. Susan R. Lundeen | Chief People Officer |
| 9 | Ms. Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer |
| 10 | Ms. Annie Yoshiyama | SVP & Corporate Controller |
Aktionärsverteilung
Aufteilung der Investoren
Größte Investoren
| Rang | Inhaber | Anteile | Wert |
|---|---|---|---|
| 1 | Pfizer Inc | 6,38% | 43,64 Mio. USD |
| 2 | BlackRock Inc | 5,53% | 37,82 Mio. USD |
| 3 | TPG GP A, LLC | 5,42% | 37,07 Mio. USD |
| 4 | Sio Capital Management, LLC | 3,86% | 26,39 Mio. USD |
| 5 | PRIMECAP Management Company | 3,80% | 26,00 Mio. USD |
| 6 | State Street Corp | 2,51% | 17,15 Mio. USD |
| 7 | Vanguard Capital Management, LLC | 2,00% | 13,71 Mio. USD |
| 8 | Citadel Advisors Llc | 1,97% | 13,46 Mio. USD |
| 9 | T. Rowe Price Associates, Inc. | 1,56% | 10,66 Mio. USD |
| 10 | Two Sigma Investments LLC | 1,56% | 10,65 Mio. USD |
| 11 | GordonMD Global Investments LP | 1,53% | 10,49 Mio. USD |
| 12 | Patient Square Capital LP | 1,46% | 10,00 Mio. USD |
| 13 | Aberdeen Group PLC | 1,45% | 9,91 Mio. USD |
| 14 | Millennium Management LLC | 1,40% | 9,60 Mio. USD |
| 15 | D. E. Shaw & Co LP | 1,36% | 9,33 Mio. USD |
| 16 | Geode Capital Management, LLC | 1,19% | 8,17 Mio. USD |
| 17 | Frazier Life Sciences Management, L.P. | 1,10% | 7,52 Mio. USD |
| 18 | Woodline Partners LP | 1,01% | 6,94 Mio. USD |
| 19 | Marshall Wace Asset Management Ltd | 1,00% | 6,83 Mio. USD |
| 20 | Dimensional Fund Advisors, Inc. | 0,94% | 6,42 Mio. USD |